References
- Asthma update - What’s in store for 2021? - hospital professional news. Available from: https://hospitalprofessionalnews.ie/2021/01/15/asthma-update-whats-in-store-for-2021/. Accessed September 12, 2021.
- Bagnasco D, Menzella F, Caminati M, et al. Efficacy of mepolizumab in patients with previous omalizumab treatment failure: real-life observation. Allergy. 2019;74(12):2539–2541. doi:10.1111/ALL.13937
- Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021;59(1):2102730. doi:10.1183/13993003.02730-2021
- Carpagnano GE, Pelaia C, D’Amato M, et al. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. Ther Adv Respir Dis. 2020;14:175346662092923. doi:10.1177/1753466620929231
- Numata T, Araya J, Miyagawa H, et al. Effectiveness of switching biologics for severe asthma patients in Japan: a single-center retrospective study. J Asthma Allerg. 2021;Volume 14:609–618. doi:10.2147/JAA.S311975
- Minami D, Kayatani H, Sato K, Fujiwara K, Shibayama T. Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab. Respirol Case Rep. 2018;7(1). doi:10.1002/RCR2.388
- Mepolizumab (Nucala®) protocol for the treatment of severe refractory eosinophilic asthma. National Clinical Programme for Respiratory Medicine; 2020. Available from: https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/protocols/mepolizumab-for-severe-refractory-eosinophilic-asthma.pdf. Accessed March 10, 2022.
- Benralizumab (Fasenra®) protocol for the treatment of severe refractory eosinophilic asthma. National Clinical Programme for Respiratory Medicine; 2020. Available from: https://www.hse.ie/eng/about/who/acute-hospitals-division/drugs-management-programme/protocols/benralizumab-for-severe-refractory-eosinophilic-asthma.pdf. Accessed April 10, 2022.
- Galkin D, Liu MC, Chipps BE, et al. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): exacerbation and safety outcomes. J Allergy Clin Immunol. 2018;141(2):AB409. doi:10.1016/J.JACI.2017.12.965
- Carpagnano GE, Resta E, Povero M, et al. Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma. Sci Rep. 2021;11(1):5453. doi:10.1038/s41598-021-84895-2